While Corlanor shows promise in chronic heart failure, its novel therapeutic target is slowing uptake.
By Louisa Joseph, Analyst
11 August 2016
The well-established treatment practices in chronic heart failure (CHF) are deterring physicians from adopting the new therapeutic strategy of Corlanor (ivabradine; Servier/Amgen/Ono Pharmaceutical), and are slowing the drug’s uptake. Corlanor gained approval for CHF patients who require ventricular rate control, as its pure heart rate (HR)-lowering properties make it an attractive alternative when the first-line beta-blockers are contraindicated. However, prescribing physicians in Europe have been slow to adopt Corlanor’s new treatment concept since its approval in Q1 2012, despite it featuring strongly in the European Society of Cardiology’s 2012 CHF guidelines. Similarly to the EU, Corlanor is expected to experience slow initial uptake in the US following its approval in April 2015. Amgen will need to promote physician education of Corlanor’s therapeutic benefits in order to increase prescription of the drug in the US, and Datamonitor Healthcare believes that physicians will require a better understanding of how patients respond to the drug before prescription rates can significantly improve.
Datamonitor Healthcare’s Chronic Heart Failure: marketed profiles cover the clinical and commercial attractiveness of currently branded therapies.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>